Skip to main content

Social Phobia

7
Pipeline Programs
4
Companies
8
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
3
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

4 companies ranked by most advanced pipeline stage

ViiV Healthcare
ViiV HealthcareNC - Durham
7 programs
2
2
2
BRL29060APhase 3
Paroxetine hydrochloride hydratePhase 3
GW876008Phase 2
vestipitant/paroxetinePhase 2
GSK561679 tabletPhase 1
+2 more programs
Prevail Therapeutics
1 program
1
LY686017Phase 21 trial
Active Trials
NCT00191022Completed185Est. Jan 2007
GSK
GSKLONDON, United Kingdom
6 programs
ParoxetineN/A1 trial
GW876008PHASE_11 trial
GW876008PHASE_21 trial
vestipitant/paroxetinePHASE_21 trial
BRL29060APHASE_31 trial
+1 more programs
Active Trials
NCT01376271Completed600Est. Sep 2013
NCT00508911Terminated4Est. Oct 2007
NCT00397722Completed299Est. Sep 2007
+3 more trials
Jerusalem Pharmaceuticals
Jerusalem PharmaceuticalsIsrael - Ramallah
1 program
Attention Bias ModificationN/A1 trial
Active Trials
NCT01909193Completed69Est. Nov 2014

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
GSKParoxetine hydrochloride hydrate
GSKBRL29060A
GSKGW876008
Prevail TherapeuticsLY686017
GSKvestipitant/paroxetine
GSKGW876008
Jerusalem PharmaceuticalsAttention Bias Modification
GSKParoxetine

Clinical Trials (8)

Total enrollment: 1,801 patients across 8 trials

NCT00318669GSKParoxetine hydrochloride hydrate

Social Anxiety Disorder Study Of Paroxetine

Start: Dec 2005Est. completion: Nov 2006390 patients
Phase 3Completed
NCT00264654GSKBRL29060A

Long-term Study Of Paroxetine in Women and Men

Start: Oct 2005Est. completion: Nov 200550 patients
Phase 3Completed
NCT00397722GSKGW876008

Treatment Of Patients With Social Anxiety Disorder

Start: Nov 2006Est. completion: Sep 2007299 patients
Phase 2Completed
NCT00191022Prevail TherapeuticsLY686017

Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder

Start: Dec 2004Est. completion: Jan 2007185 patients
Phase 2Completed
NCT00403962GSKvestipitant/paroxetine

A Combination Therapy In Patients With Social Anxiety Disorder

Start: Nov 2004Est. completion: Aug 2005204 patients
Phase 2Completed
NCT00508911GSKGW876008

A Study To Evaluate The Effect Of GW876008 On The Pharmacokinetics Of Oral Contraceptive Pills

Start: Jun 2007Est. completion: Oct 20074 patients
Phase 1Terminated
NCT01909193Jerusalem PharmaceuticalsAttention Bias Modification

CBT vs. ABM vs. for Social Anxiety

Start: Jan 2011Est. completion: Nov 201469 patients
N/ACompleted
NCT01376271GSKParoxetine

Special Drug Use Investigation for PAXIL (Paroxetine) Social Anxiety Disorder (Long-term)

Start: Jan 2010Est. completion: Sep 2013600 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.